Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model

  • Bae, Yun Jung (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Yoon, Young Il (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Yoon, Tae-Jong (Department of Applied Bioscience, College of Life Science, CHA University) ;
  • Lee, Hak Jong (Department of Radiology, Seoul National University Bundang Hospital)
  • Received : 2015.09.07
  • Accepted : 2016.04.14
  • Published : 2016.07.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the effectiveness of ultrasound and microbubble-liposome complex (MLC)-mediated delivery of siRNA and doxorubicin into prostate cancer cells and its therapeutic capabilities both in vitro and in vivo. Materials and Methods: Microbubble-liposome complexes conjugated with anti-human epidermal growth factor receptor type 2 (Her2) antibodies were developed to target human prostate cancer cell lines PC-3 and LNCaP. Intracellular delivery of MLC was observed by confocal microscopy. We loaded MLC with survivin-targeted small interfering RNA (siRNA) and doxorubicin, and delivered it into prostate cancer cells. The release of these agents was facilitated by ultrasound application. Cell viability was analyzed by MTT assay after the delivery of siRNA and doxorubicin. Survivin-targeted siRNA loaded MLC was delivered into the xenograft mouse tumor model. Western blotting was performed to quantify the expression of survivin in vivo. Results: Confocal microscopy demonstrated substantial intracellular uptake of MLCs in LNCaP, which expresses higher levels of Her2 than PC-3. The viability of LNCaP cells was significantly reduced after the delivery of MLCs loaded with siRNA and doxorubicin ($85.0{\pm}2.9%$), which was further potentiated by application of ultrasound ($55.0{\pm}3.5%$, p = 0.009). Survivin expression was suppressed in vivo in LNCaP tumor xenograft model following the ultrasound and MLC-guided delivery of siRNA ($77.4{\pm}4.90%$ to $36.7{\pm}1.34%$, p = 0.027). Conclusion: Microbubble-liposome complex can effectively target prostate cancer cells, enabling intracellular delivery of the treatment agents with the use of ultrasound. Ultrasound and MLC-mediated delivery of survivin-targeted siRNA and doxorubicin can induce prostate cell apoptosis and block survivin expression in vitro and in vivo.

Keywords

Acknowledgement

Supported by : Seoul National University Bundang Hospital

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29 https://doi.org/10.3322/caac.20138
  2. Kawasaki H, Taira K, Morris KV. siRNA induced transcriptional gene silencing in mammalian cells. Cell Cycle 2005;4:442-448 https://doi.org/10.4161/cc.4.3.1520
  3. Barik S. Silence of the transcripts: RNA interference in medicine. J Mol Med (Berl) 2005;83:764-773 https://doi.org/10.1007/s00109-005-0690-0
  4. Hasan W, Chu K, Gullapalli A, Dunn SS, Enlow EM, Luft JC, et al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett 2012;12:287-292 https://doi.org/10.1021/nl2035354
  5. Becker AL, Orlotti NI, Folini M, Cavalieri F, Zelikin AN, Johnston AP, et al. Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano 2011;5:1335-1344 https://doi.org/10.1021/nn103044z
  6. Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011;32:2662-2672 https://doi.org/10.1016/j.biomaterials.2010.12.029
  7. Yoon YI, Kwon YS, Cho HS, Heo SH, Park KS, Park SG, et al. Ultrasound-mediated gene and drug delivery using a microbubble-liposome particle system. Theranostics 2014;4:1133-1144 https://doi.org/10.7150/thno.9945
  8. Wang X, Liang HD, Dong B, Lu QL, Blomley MJ. Gene transfer with microbubble ultrasound and plasmid DNA into skeletal muscle of mice: comparison between commercially available microbubble contrast agents. Radiology 2005;237:224-229 https://doi.org/10.1148/radiol.2371040805
  9. Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ 2001;322:1222-1225 https://doi.org/10.1136/bmj.322.7296.1222
  10. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008;60:1153-1166 https://doi.org/10.1016/j.addr.2008.03.005
  11. Wu Y, Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G, et al. Binding and lysing of blood clots using MRX-408. Invest Radiol 1998;33:880-885 https://doi.org/10.1097/00004424-199812000-00006
  12. Malmberg J, Tolmachev V, Orlova A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer: cellular processing of [(111)In]-labeled CHX-A"DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Exp Ther Med 2011;2:523-528 https://doi.org/10.3892/etm.2011.217
  13. Ling YX, Tao J, Fang SF, Hui Z, Fang QR. Downregulation of Id1 by small interfering RNA in prostate cancer PC3 cells in vivo and in vitro. Eur J Cancer Prev 2011;20:9-17 https://doi.org/10.1097/CEJ.0b013e32833ebaa0
  14. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265 https://doi.org/10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G
  15. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology 2007;69:142-146 https://doi.org/10.1016/j.urology.2006.09.015
  16. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006;5:179-186 https://doi.org/10.1158/1535-7163.MCT-05-0132
  17. Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K. Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. J Urol 2011;185:1497-1503 https://doi.org/10.1016/j.juro.2010.12.005
  18. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002;51:133-140 https://doi.org/10.1002/pros.10061
  19. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24:2474-2482 https://doi.org/10.1038/sj.onc.1208490
  20. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 2010;78:1095-1103 https://doi.org/10.1016/j.ijrobp.2009.09.007
  21. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D, et al. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res 2009;69:4468-4475 https://doi.org/10.1158/0008-5472.CAN-08-4423
  22. Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 2009;41:223-230 https://doi.org/10.1093/abbs/gmp005
  23. Skyba DM, Price RJ, Linka AZ, Skalak TC, Kaul S. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation 1998;98:290-293 https://doi.org/10.1161/01.CIR.98.4.290

Cited by

  1. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy vol.37, pp.6, 2017, https://doi.org/10.3892/or.2017.5593
  2. Mechanism of Cellular Uptake to Optimized AuNP Beacon for Tracing mRNA Changes in Living Cells vol.35, pp.2, 2016, https://doi.org/10.1002/ppsc.201700331
  3. Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy vol.20, pp.2, 2016, https://doi.org/10.2174/1389450119666180731095441
  4. The Role of Ultrasound-Driven Microbubble Dynamics in Drug Delivery: From Microbubble Fundamentals to Clinical Translation vol.35, pp.31, 2016, https://doi.org/10.1021/acs.langmuir.8b03779
  5. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer vol.7, pp.3, 2016, https://doi.org/10.3390/bioengineering7030091
  6. Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy vol.12, pp.5, 2021, https://doi.org/10.1002/wrna.1648
  7. USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages vol.23, pp.None, 2016, https://doi.org/10.1016/j.omto.2021.08.010